Global Full-Service CDMO Market Growth (Status and Outlook) 2024-2030

Global Full-Service CDMO Market Growth (Status and Outlook) 2024-2030

A Full-Service Contract Development and Manufacturing Organization (CDMO) is a company that provides comprehensive services across the entire drug development and manufacturing lifecycle, from early-stage development to commercial-scale production. These organizations offer a wide range of services to pharmaceutical and biotechnology companies, allowing them to outsource various aspects of drug development and manufacturing to external partners with specialized expertise and capabilities.

The global Full-Service CDMO market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Full-Service CDMO Industry Forecast” looks at past sales and reviews total world Full-Service CDMO sales in 2022, providing a comprehensive analysis by region and market sector of projected Full-Service CDMO sales for 2023 through 2029. With Full-Service CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Full-Service CDMO industry.

This Insight Report provides a comprehensive analysis of the global Full-Service CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Full-Service CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Full-Service CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Full-Service CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Full-Service CDMO.

United States market for Full-Service CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Full-Service CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Full-Service CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Full-Service CDMO players cover Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Full-Service CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type:
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO

Segmentation by Application:
Pharmaceutical Company
Biotechnology Company

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO

Segmentation by Application:
Pharmaceutical Company
Biotechnology Company

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL

Please note: The report will take approximately 2 business days to prepare and deliver.